Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923829 | 1.00 | TDP1 (0.48) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| SCHEMBL29733565 | 1.00 | TDP1 (0.48) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| Water SCHEMBL4813848 | 0.98 | TDP1 (0.47) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| SCHEMBL29673261 | 0.93 | TDP1 (0.55) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| SCHEMBL1489599 | 0.93 | TDP1 (0.55) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| SCHEMBL424471 | 0.93 | TDP1 (0.55) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| SCHEMBL697038 | 0.93 | TDP1 (0.55) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| Water SCHEMBL9529895 | 0.91 | TDP1 (0.53) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| Water SCHEMBL8461991 | 0.91 | TDP1 (0.53) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| SCHEMBL28794540 | 0.84 | ALOX15 (0.45) | RAB9ANPC1ALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114763339-A | Process for the preparation of triazine derivatives | 江苏恒瑞医药股份有限公司 | 2022-07-19 | — | — | CN | claimed |
| EP-4739669-A1 | SODIUM CHANNEL BLOCKERS | Novartis AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| CN-122010912-A | Antiviral 1, 3-dioxoindene compounds | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010905-A | Pyrazolyl derivatives as anticancer agents | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4665734-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-4626890-A1 | RIBOCICLIB SALTS AND FORMULATIONS THEREOF | KRKA, d.d., Novo mesto (SI) | 2025-10-08 | — | — | EP | disclosed |
| EP-4436662-B1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| US-20250223297-A1 | NOVEL RAPAMYCIN DERIVATIVES | NOVARTIS AG (CH) | 2025-07-10 | — | — | US | disclosed |
| EP-4577550-A1 | NOVEL NLRP3 INFLAMMASOME INHIBITORS | Hangzhou Highlightll Pharmaceutical Co., Ltd. (CN) | 2025-07-02 | — | — | EP | disclosed |
| US-20250197376-A1 | PYRAZINE AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2025-06-19 | — | — | US | disclosed |
| WO-2009091561-A1 | PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4] NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS | TARGACEPT, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| CN-101273048-A | Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes | NOVARTIS AG (CH) | 2008-09-24 | — | — | CN | disclosed |
| EP-1911754-A1 | Dipeptidyl peptidase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| CN-1886374-A | Process for preparing (3-oxo-2,3-dihydro-1h-isoindol-1-yl) acetylguanidine derivatives | AVENTIS PHARMA GMBH (DE) | 2006-12-27 | — | — | CN | disclosed |
| CN-1146992-A | Process for preparation of intermediate (R)-3-amino-5-methoxychroman | ASTRA AB (SE) | 1997-04-09 | — | — | CN | disclosed |
| CN-1072411-A | Novel active compounds for use in therapy | ASTRA AB (SE) | 1993-05-26 | — | — | CN | disclosed |
| EP-0160502-B1 | Improvements in and relating to octahydrothiazolo[4,5-g]quinolines | ELI LILLY AND COMPANY (US) | 1991-09-25 | — | — | EP | disclosed |
| EP-0172697-B1 | Octahydro-oxazolo[4,5-g]quinolines | ELI LILLY AND COMPANY (US) | 1991-09-25 | — | — | EP | disclosed |
| EP-0139393-B1 | PYRIMIDO(4,5-G)QUINOLINES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 1991-05-15 | — | — | EP | disclosed |
| EP-0347229-A1 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197376-A1 | PYRAZINE AMIDE DERIVATIVES | SIRT5, GLS2, ARG2 | TDP1 4417/4885RAB9A 1611/4885NPC1 1853/4885 |
| US-20250223297-A1 | NOVEL RAPAMYCIN DERIVATIVES | MTOR, RICTOR, RPTOR | TDP1 2721/4885RAB9A 160/4885NPC1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.